靶向代谢组学鉴别内分泌性与原发性高血压
本研究基于欧洲多中心ENSAT-HT回顾性数据,对282例成人(原发性高血压59例,内分泌性高血压223例,含库欣综合征40例、原发性醛固酮增多症107例、嗜铬细胞瘤/副神经节瘤76例)血样行靶向代谢组学检测,采用经典方法与机器学习方法筛选差异代谢物,发现两方法共同识别16种代谢物,受试者工作特征曲线下面积分别为0.86和0.83,提示代谢组学在鉴别两类高血压方面具有较好性能。
要点
- 靶向代谢组学可区分原发性高血压与内分泌性高血压,共同差异代谢物16种。
- 经典方法筛选的15种代谢物构建模型AUC为0.86,机器学习方法为0.83。
- 研究涵盖库欣综合征、原发性醛固酮增多症及嗜铬细胞瘤/副神经节瘤三类内分泌性高血压。
核心结论
- 靶向代谢组学可识别原发性高血压与内分泌性高血压之间不同的代谢模式,并展现出有希望的鉴别性能。
研究设计与样本
- 欧洲多中心ENSAT-HT研究的回顾性分析,纳入282例成人患者(52%女性,平均年龄49岁),包括原发性高血压59例和内分泌性高血压223例(库欣综合征40例、原发性醛固酮增多症107例、嗜铬细胞瘤/副神经节瘤76例)。
- 对储存血样采用液相色谱-质谱联用进行靶向代谢组学检测,并使用经典方法(系列单变量和多变量分析)与机器学习方法(随机森林)识别差异代谢物。
主要发现
- 在155种可进行统计分析的代谢物中,经典方法识别出31种在原发性高血压与内分泌性高血压间有差异的代谢物,机器学习方法识别出27种。
- 两种方法共同识别出16种差异代谢物:C9、C16、C16:1、C18:1、C18:2、精氨酸、天冬氨酸、谷氨酸、鸟氨酸、亚精胺、lysoPCaC16:0、lysoPCaC20:4、lysoPCaC24:0、PCaeC42:0、SM C18:1、SM C20:2。
- 基于经典方法前15种代谢物构建的受试者工作特征曲线下面积(AUC)为0.86,基于机器学习方法前15种代谢物的AUC为0.83。
临床怎么用
- 靶向代谢组学或可作为辅助工具,帮助在高血压患者中识别需要进一步内分泌筛查的可疑内分泌性高血压个体。
局限性
- 研究为回顾性分析,样本来自储存血样,结论需在前瞻性队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Identification of patients with endocrine forms of hypertension (EHT) (primary hyperaldosteronism [PA], pheochromocytoma/paraganglioma [PPGL], and Cushing syndrome [CS]) provides the basis to implement individualized therapeutic strategies. Targeted metabolomics (TM) have revealed promising results in profiling cardiovascular diseases and endocrine conditions associated with hypertension. OBJECTIVE: Use TM to identify distinct metabolic patterns between primary hypertension (PHT) and EHT and test its discriminating ability. METHODS: Retrospective analyses of PHT and EHT patients from a European multicenter study (ENSAT-HT). TM was performed on stored blood samples using liquid chromatography mass spectrometry. To identify discriminating metabolites a "classical approach" (CA) (performing a series of univariate and multivariate analyses) and a "machine learning approach" (MLA) (using random forest) were used.The study included 282 adult patients (52% female; mean age 49 years) with proven PHT (n = 59) and EHT (n = 223 with 40 CS, 107 PA, and 76 PPGL), respectively. RESULTS: From 155 metabolites eligible for statistical analyses, 31 were identified discriminating between PHT and EHT using the CA and 27 using the MLA, of which 16 metabolites (C9, C16, C16:1, C18:1, C18:2, arginine, aspartate, glutamate, ornithine, spermidine, lysoPCaC16:0, lysoPCaC20:4, lysoPCaC24:0, PCaeC42:0, SM C18:1, SM C20:2) were found by both approaches. The receiver operating characteristic curve built on the top 15 metabolites from the CA provided an area under the curve (AUC) of 0.86, which was similar to the performance of the 15 metabolites from MLA (AUC 0.83). CONCLUSION: TM identifies distinct metabolic pattern between PHT and EHT providing promising discriminating performance.
引用
- Erlic Z, Reel P, Reel S, et al. Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. J Clin Endocrinol Metab. 2021. PMID: 33382876. doi:10.1210/clinem/dgaa954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。